Revelation Biosciences, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023. Revelation is a clinical-stage biopharmaceutical company developing innate immune therapeutics and diagnostics. It has never generated revenue and does not expect product sales for at least several years, if ever.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $0.91 million | $0.98 million | $1.43 million | $4.66 million |
| General and administrative | $1.02 million | $0.88 million | $2.12 million | $3.79 million |
| Operating loss | $1.93 million | $1.86 million | $3.55 million | $8.45 million |
| Net income (loss) | $(1.45) million | $(1.83) million | $4.71 million | $(8.45) million |
Six-month 2023 net income reflects an $8.17 million noncash gain from remeasuring warrant liabilities; it does not indicate profitable operations. Q2 net loss narrowed year over year, although operating loss increased modestly. No meaningful revenue or profit margin is reported.
- Liquidity: Cash and cash equivalents were $15.71 million at June 30, 2023, versus $5.25 million at December 31, 2022. Current assets were $15.96 million and current liabilities $4.62 million; stockholders’ equity was $11.41 million.
- Cash flow: Operating activities used $3.57 million in the first half, compared with $8.54 million in the prior-year period. Financing activities provided $14.03 million, principally net proceeds from the February 2023 public offering. Cash increased by $10.46 million.
- Debt and commitments: The balance sheet reports no outstanding borrowings. Contractual operating lease payments were $57,780, all due within one year. Current liabilities include a $302,039 warrant liability and $2.91 million of deferred underwriting commissions.
Material changes and notable developments
- R&D expense fell $3.22 million for the first half, mainly because prior-year REVTx-99a clinical-study spending ended; spending on other programs and manufacturing increased. Management expects R&D expense to increase as development continues.
- G&A expense declined $1.67 million for the first half, primarily due to lower insurance and professional-service costs; it rose $139,000 in Q2, including higher advisory, legal and consulting fees.
- The February 2023 public offering generated $14.0 million net. Common shares outstanding increased from 682,882 at December 31, 2022 to 6,297,303 at June 30, 2023, including shares issued through cashless warrant exercises. The 1-for-35 reverse split and increase in authorized common shares to 500 million also took effect in February.
- Nasdaq notified the company in February 2023 that it had regained compliance with listing requirements.
Outlook, risks and contingencies
- Going concern: Management states that available cash is not expected to sustain operations for one year after the financial statements were issued, raising substantial doubt about the company’s ability to continue as a going concern. It plans to seek additional equity or debt financing, but financing may not be available on acceptable terms or at all. Failure to raise funds could force delays, reductions or termination of development programs.
- The company expects continued operating losses and negative operating cash flow, and has no specific revenue or profitability guidance. Clinical timelines, development costs and the probability of product success remain uncertain.
- Litigation: LifeSci Capital seeks approximately $2.7 million in cash and $2.6 million in equity for disputed fees; the court denied its summary-judgment motion. A separate IPO underwriter demanded $655,000 in unpaid fees. The filing records $2.91 million in deferred underwriting commissions but does not record additional amounts whose liability cannot be determined. A-IR Clinical Research seeks £1.6 million plus interest and costs over disputed study invoices; no liability is recorded because the amount, if any, cannot be determined.
- The filing reports no material changes to the risk factors in the 2022 Form 10-K. Management said disclosure controls were effective at the reasonable-assurance level and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Cash runway assumptions, planned financing needs, and whether new capital is available on acceptable terms.
- Development progress, funding requirements and timelines for REVTx-300, REVTx-100, REVTx-200, REVTx-99b and REVDx-501.
- The potential dilution and accounting impact of outstanding warrants, including the remaining Class C warrants and their fair-value remeasurement.
- Updates on LifeSci Capital and A-IR litigation, the separate underwriter demand, and any resulting cash or equity obligations.
- Whether reduced prior-year R&D spending reflects program timing and completion of REVTx-99a study work, rather than a sustained reduction in future development costs.